Cargando…
Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress
BACKGROUND: Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1, a key transcription factor in hematopoiesis, also involve...
Autores principales: | She, Chunhua, Wu, Chao, Guo, Weihua, Xie, Yongjie, Li, Shouyi, Liu, Weishuai, Xu, Chao, Li, Hui, Cao, Pei, Yang, Yanfang, Wang, Xiuchao, Chang, Antao, Feng, Yukuan, Hao, Jihui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494371/ https://www.ncbi.nlm.nih.gov/pubmed/37697370 http://dx.doi.org/10.1186/s13046-023-02814-x |
Ejemplares similares
-
UPR proteins IRE1 and PERK switch BiP from chaperone to ER stress sensor
por: Kopp, Megan C, et al.
Publicado: (2019) -
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
por: Fu, Danqi, et al.
Publicado: (2023) -
Nucleofection induces transient eIF2α phosphorylation by GCN2 and PERK
por: Anderson, Bart R., et al.
Publicado: (2012) -
Avarol Induces Apoptosis in Pancreatic Ductal Adenocarcinoma Cells by Activating PERK–eIF2α–CHOP Signaling
por: Namba, Takushi, et al.
Publicado: (2015) -
Regulation of PERK Signaling and Leukemic Cell Survival by a Novel Cytosolic Isoform of the UPR Regulator GRP78/BiP
por: Ni, Min, et al.
Publicado: (2009)